Page last updated: 2024-08-23

idarubicin and Hodgkin Disease

idarubicin has been researched along with Hodgkin Disease in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (40.00)18.2507
2000's4 (40.00)29.6817
2010's1 (10.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Angelov, D; Cotter, AG; Fay, M; Lambert, JS; McGettrick, P; McGinty, T; O'Kelly, B; Sheehan, G1
Cotta, CV; Khan, G; Pohlman, B; Sweetenham, J; Wesolowski, R1
Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A1
Kansu, E; Kars, A; Koc, Y; Oyan, B; Ozdemir, E; Tekuzman, G; Turker, A1
Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B1
Borchmann, P; Diehl, V; Engert, A; Schnell, R1
Kuraishi, Y; Masaoka, T; Ogawa, M; Ohashi, Y; Ohno, R; Urabe, A1
Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E1
Devine, S; Heffner, LT; Jones, TW; Lonial, S; Smith, KJ; Waller, EK; Winton, EF; Yeager, AM1
Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT1

Reviews

1 review(s) available for idarubicin and Hodgkin Disease

ArticleYear
New drugs in the treatment of Hodgkin's disease.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9 Suppl 5

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bendamustine Hydrochloride; Deoxycytidine; Drug Therapy; Gemcitabine; Hodgkin Disease; Humans; Idarubicin; Immunotoxins; Nitrogen Mustard Compounds; Vinblastine; Vinorelbine

1998

Trials

5 trial(s) available for idarubicin and Hodgkin Disease

ArticleYear
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:9

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous

2005
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
    Leukemia & lymphoma, 1998, Volume: 31, Issue:3-4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis

1998
[Clinical effect of idarubicin on malignant lymphoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:9

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Female; Hodgkin Disease; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged

1999
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
    Leukemia & lymphoma, 2000, Volume: 36, Issue:5-6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Salvage Therapy; Survival Analysis

2000
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Bone marrow transplantation, 2000, Volume: 26, Issue:6

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine

2000

Other Studies

4 other study(ies) available for idarubicin and Hodgkin Disease

ArticleYear
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
    British journal of haematology, 2020, Volume: 190, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Bleomycin; Coronavirus Infections; COVID-19; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Hydroxychloroquine; Idarubicin; Mediastinal Neoplasms; Pandemics; Pneumonia, Viral; Positron-Emission Tomography; Prednisone; Procarbazine; SARS-CoV-2; Treatment Outcome; Vinblastine; Vincristine

2020
Successful treatment of Hodgkin lymphoma and acute leukemia.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:1

    Topics: Adult; Biopsy; Bone Marrow Cells; Cytarabine; Hodgkin Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Remission Induction

2010
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infections; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome

2005
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
    Leukemia & lymphoma, 1999, Volume: 35, Issue:5-6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine

1999